### June 2025 Dr. Soliman Abdel Kader Fakeeh Hospital Co. Investment Update



# Expansion delays across the board pushes forecasted revenue pipeline back; we downgrade our TP to 44.6/share at a maintained "Neutral" recommendation

Fakeeh's Q1-25 performance was burdened by Ramadan & Eid holidays and increased costs to post a net income of SAR 72.2mn (down 0.7% Y/Y and 2.1% Q/Q). While revenues reached SAR 701mn (up 3% Y/Y and down 5.6% Q/Q), patient volumes when normalized for Ramadan and Eid would have grown 9% Y/Y in a sign of healthy operational metrics. While decreasing finance charges supported the quarter, costs of sales and operating expenses mounted up from hiring inflation and likely some costs ahead of the Madinah hospital opening, which came live by April 2025; declining GPMs by 260bps Y/Y to reach 25.1%, and OPEX to revenue increasing by 180bps Y/Y to reach 14.4%. Going forward, Fakeeh's next years are categorized by an aggressive expansion campaign (doubling its current 835 bed capacity). Much of the expansions were delayed, and while we account for their maturity in our forecast timelines, we see more pressures amounting from competition to challenge costs as well as ramp up speeds. We revise our TP down to 44.6/share, at a maintained "Neutral" recommendation.

Ramadan sequentially pressured Q1-25, while supported by Riyadh hospital turnaround; higher expenses built up, likely ahead of Madinah opening, but offset by lower finance charges: Fakeeh ended Q1-25 recording a bottom line of SAR 72.2mn (down 0.7% Y/Y and 2.1% Q/Q), while pressured by more Ramadan days in Q1-25 and increasing expenses during the quarter. Revenue at SAR 701mn (up 3.0% Y/Y and down 5.6% Q/Q) reflected the pressures of a full Q1 of Ramadan, which in 2025 saw a slowdown of almost 7 working days as compared to Q1-24. The turnaround of the Riyadh hospital, however, supported the top line with an SAR 18mn growth in its contribution to revenues (Y/Y). Patient growth of 9% Y/Y when normalized for impact of Ramadan an Eid is a notable feature achieved during the quarter in a sign of solid operational metrics alongside the 80% occupancy rate reached. Cost of revenue increased 6.7% to reach SAR 524.9mn as a result of competitive salary adjustments in light of increased competition in the sector, and likely due to Madina pre-operating expenses. This resulted in a GPM of 25.1% (down 260bps Y/Y, and up 290bps sequentially as Q4-24 saw one-off costs related to the NEOM contract). Operating expenses displayed similar trends, as OPEX to revenues increased to 14.4% of revenues (up from 12.6% Y/Y, and 12.5% Q/Q). The increase costs during Q1-25 were partially offset by a significant decline in finance charges (Y/Y) from SAR 39mn to SAR 9.9mn during the guarter, as Fakeeh settled almost 70% of the amount of debt that was held this time last year. Excluding the effects of the Hajj contract tender awarded, we expect similar trends to carry onto Q2-25 as Fakeeh ramps up manpower in Madinah and increases salary spending in Jeddah where competition is increasing.

Expansion delays of upcoming four projects (expanding at c. 100% of current beds capacity), including the delay of now-open Madinah Hospital, pushes timeline of our previous forecasts: Fakeeh eyes an impressive expansion campaign to define the long term growth story for the firm, which will be driven by its plan to open up four new greenfield and brownfield facilities: DSFH Jeddah Surgery Tower (140 beds by H1-28), HEAL Hospital Jeddah (200 beds by H1-28), DSFH Makkah (200 beds by H1-28), and DSFH South Obhur Jeddah (300 beds by H2-28). All of which have been delayed by almost 1 half of a year from the initial timelines announced; including the now opened Madinah hospital which was delayed till Q2-25. These delays brought our FY23-30E revenue and net income pre non-controlling interest CAGR estimates down from 17.3% and 22.3%, respectively, to 15.2% and 17.5% for the same period. We see that the story remains somewhat similar, just delayed and extended, as we expect FY32 to reflect the delayed ramp ups of the facilities. Atop the expansion delays, we extend our forecasted ramp up times, due to the more apparent competition in the sector which has been weighing down on patient attraction across providers, as well increasing costs on staffing and operating. We expect significant cost pressures to take place during FY28-29, where all the expansions at 100% of current capacities would begin operations and ramp up. This takes our operating margins estimates to contract by 210bps from FY24 levels (12.9%) to reach 10.8% by FY28E before improving gradually.

; 1	Recommendation	Neutral
s	Target Price (SAR)	44.6
d	Upside / (Downside)*	5.8%

Source: Tadawul \*prices as of 29th of May 2025

#### Key Financials

in SAR mn, (unless specified)	FY24	FY25E	FY26E	FY27E
Revenue	2,791	3,156	3,467	3,764
Growth %	19.95%	13.07%	9.86%	8.57%
Gross Profit	699	777	857	949
EBIT	359	375	435	500
Net Income*	288	355	368	405
Growth %	2.85%	23.57%	3.65%	9.93%
EPS	1.32	1.53	1.59	1.75
DPS	0.30	0.30	0.30	0.35
Source: Company repor	ts, Aljazira (	Capital *Pos	t non-cont	rolling

interest

#### Key Ratios

	FY24	FY25E	FY26E	FY27E
Gross Margin	25.05%	24.63%	24.71%	25.21%
OP Margin	12.87%	11.87%	12.64%	13.37%
Net Margin	10.30%	11.26%	10.62%	10.76%
EBITDA Margin	18.4%	19.0%	21.0%	22.4%
RoE	12.6%	10.3%	9.9%	10.1%
P/E (x)	51.4	27.6	26.6	24.2
P/B (x)	4.7	2.7	2.5	2.4
EV/EBITDA (x)	30.6	17.2	15.2	13.4
Dividend Yield	0.4%	0.7%	0.7%	0.8%
Source: Company repor	rts, Aljazira (	Capital Res	earch	

#### Key Market Data

Ney Market Data	
Market Cap (SAR bn)	9.65
YTD%	-37.9%
52 weeks (High)/(Low)	72.90/40.55
Share Outstanding (mn)	232
Source: Company reports, Aljazira Capital F	Research

Price Performance



Source: Tadawul, AlJazira Capital Research

Equity Analyst Ibrahim Elaiwat +966 11 2256115 i.elaiwat@Aljaziracapital.com.sa



# Dr. Soliman Abdel Kader Fakeeh Hospital Co. Investment Update

**June 2025** 



One-off SAR 80mn Hajj contract expected to support initial Madinah ramp up costs during Q2-25; Gross margin trajectory to remain challenged by hefty expansion campaign as Fakeeh scales up: Fakeeh secured an SAR 80mn contract to provide ambulatory services during Hajj season (Q2-25) which we expect to offset some of the cost damage incurred by Madinah Hospital's opening visible by Q2-25. The Hajj contract, at a cost+ framework, is expected to be gross margin accretive for the comparatively low gross margin group. However, while we expect the contract to offset some pressures in Q2-25, we expect the one-off engagement to contribute modestly to gross margins by only 10bps on an annual basis. Our gross margin estimates for FY25 reach 24.6%, which seem like a minor decline from FY24's GPM of 25.0% yet we consider the one off costs incurred in FY24 related to the NEOM contract; however our estimates remain a way shorter from FY22-23 levels of 30.4% and 26.5%, as a result of Madinah pressures to take place, and expected pre-operating costs for three medical centers on the horrizon to start rolling out by H2-25. Our forecasted GPM trajectory remains muted as the firm undergoes significant hospital and clinics expansions, mostly in FY28, where we expect GPMs to reach 23.5% before improving gradually. Management indicate optimism in more tender awardations to come, and an active approach towards Vision 2030 mega project tenders; such engagements provide an upside to Fakeeh's revenues, but also to enhance its cost base as it sits subpar to sector averages (FY24 GPM at 25.0% vs 36.2% sector average, and net margin at 10.3% vs 18.3% market average).

Estimated SAR 3.2bn CAPEX ahead from FY25-28 to require a re-onloading of debt: The group shed almost 70% of its debt it carried during Q1-24, bringing its net debt to equity down to almost 0x in Q1-25, and a debt to equity to 15% (down from 130% Y/Y). Going forward, however, as the firm braces for the set of expansions underway with four hospitals coming in by FY28 along with clinic expansions along the way, we expect Fakeeh to face a CAPEX bill of SAR 3.2bn over FY25-28E mainly due to expansion campaign ahead. While some costs are expected to take place in FY25, we expect the bulk of CAPEX to take place between FY26-27E where SAR 2bn are expected to be incurred. We expect D/E to peak by FY27E at 0.42x as compared to 0.16x in FY24 before unlevering gradually. Along with the cashflows from operations as well as debt to fund CAPEX, we expect dividend payout ratios to be able to be safely maintained at early 20% for the coming periods.

**AJC view and valuation:** Fakeeh possesses solid brand equity driven by a reputation of complex procedures and a long-standing history in the Western region. Its solid operational metrics, at the group level, and at the recently acquired Riyadh hospital is a good signal on its capabilities and patient attraction. However, Fakeeh's financial performance remains constricted as compared to its peers, summarized by an ROAE of 12.6% vs the sector's 19.6%, as well as subpar margins at the gross, operating, and net levels. We see its expansion campaign to be a medium term challenge to its financial performance as Fakeeh scales to double up from its now 835 bed operation. Its involvement in government tenders and Mega projects could however enhance its financial profile along the way during its campaign. While considering the maturity of the delayed expansions, we revise down our forecasted revenue & net income FY23-30E CAGRs to 15.2% and 17.5%, and TP to **SAR 44.6 per share** due to competition extending ramp up speed and cost base. We value the stock by way of 50% PE valuation (30x on FY25E) blended with 50% DCF (terminal growth rate=2.75% and WACC=10.4%). We maintain a "**Neutral**" recommendation on the stock which currently trades at a forward PE of 27.6x.

#### Valuation Summary (SAR /share):

	Target Price	Weight	Weighted TP
PE (30x on FY25E)	45.9	50%	23.0
DCF	43.3	50%	21.7
Target Price (SAR/share):			44.6 /share

Source: AlJazira Capital Research \*Sums may differ due to rounding

زيرة كابيتال

الحزبة للأسواق المالية ALJAZIRA CAPITAL


2

Upside risks to valuation:	Downside risks to valuation:
More margin accretive tender awardations and Vision 2030 engagements	<ul> <li>More than expected competition pressures in Western Region</li> </ul>
Quicker than expected ramp up of facilities	Further delays or project cancellations
• DRG pricing in favor of its complex nature of operations	Higher than expected talent retention and attraction costs

# Fig 2: Cost pressures to mount while expansions ramp up



Fig 3: Doubling current capacity of 835 beds, via four projects by FY28



Source: Company reports, Aljazira Capital Research

### June 2025

# Dr. Soliman Abdel Kader Fakeeh Hospital Co.

### **Investment Update**



Amount in SARmn, unless otherwise specified	FY23	FY24	FY25E	FY26E	FY27E	FY28E	FY29E	FY30E
Income statement								
Revenues	2,327	2,791	3,156	3,467	3,764	4,651	5,638	6,271
Y/Y	15.62%	19.95%	13.07%	9.86%	8.57%	23.56%	21.23%	11.21%
Cost of revenue	(1,710)	(2,092)	(2,378)	(2,610)	(2,815)	(3,560)	(4,302)	(4,751
Gross profit GPM	617 26.50%	<mark>699</mark> 25.05%	777 24.63%	<mark>857</mark> 24.71%	949 25.21%	1,091 23.46%	1,336	1,520 24.24%
General & administration expense	(243)	(279)	(339)	(366)	(390)	23.40% (518)	<b>23.70%</b> (610)	(626)
Selling & Marketing	(49)	(59)	(59)	(53)	(57)	(69)	(73)	(020)
ECL	(11)	(13)	(19)	(17)	(17)	(20)	(24)	(25)
Other income	21	11	13	17	19	21	25	27
Operating profit	334	359	375	438	503	504	654	821
Y/Y	-12.61%	7.51%	4.31%	16.96%	14.89%	0.23%	29.70%	25.47%
OP Margin	14.35%	12.87%	11.87%	12.64%	13.37%	10.85%	11.60%	13.09%
Financial charges Finance income	(122) 43	(96) 24	(49) 27	(77) 10	(94) 10	(86) 9	(64) 7	(46) 8
EBITDA	474	514	599	729	843	874	1,053	1,257
Y/Y	-8.14%	8.44%	16.45%	21.76%	15.51%	3.72%	20.54%	19.30%
ncome before zakat	255	287	353	371	419	427	598	782
Zakat	(23)	(23)	(29)	(30)	(34)	(35)	(48)	(64)
Net income	232	264	324	341	385	393	550	718
Net Income Post Minority Interest	280	288	355	368	405	410	562	722
	-14.32%	2.85%	23.57%	3.65%	9.93%	1.27%	37.00%	28.53%
VI Margin	12.02%	10.30%	11.26%	10.62%	10.76%	8.82%	9.96%	11.51%
EPS (SAR) DPS (SAR)	1.21 5.00	1.32 0.30	1.53 0.30	1.59 0.30	1.75 0.35	1.77 0.40	2.42 0.50	3.11 0.65
Balance sheet	5.00	0.00	0.00	0.00	0.00	0.40	0.50	0.05
Assets								
Cash & equivalent	214	534	156	130	228	183	233	278
Receivables	746	896	919	1,000	1,076	1,316	1,581	1,741
Other current assets	428	418	450	486	520	621	732	800
Fotal current assets	1,388	1,848	1,525	1,616	1,823	2,120	2,545	2,818
Property plant & equipment Right of use assets	1,635 521	2,096 505	2,840 486	3,845 523	4,333 557	4,335 597	4,217 586	4,117 557
Fotal assets	4,232	5,322	5,728	6,868	7,605	7,963	8,284	8,461
Liabilities & owners' equity	4,202	0,022	0,120	0,000	1,000	1,000	0,204	0,401
Short term debt	494	215	244	500	601	510	357	143
Trade payables	275	373	371	412	453	566	693	780
Other current liabilities	296	351	343	376	407	490	576	634
Total current liabilities	1,066	938	958	1,288	1,460	1,566	1,626	1,556
_ease liabilities – non-current	496	481	464	510	561	628	659	699
Long term loans	1,196	322	453	929	1,115	948	664	265
Other non-current liabilities Fotal non-current liabilities	219	261	278 <b>1,195</b>	296	321	374	453	491
Share capital	<b>1,911</b> 200	<b>1,063</b> 232	232	<b>1,736</b> 232	<b>1,997</b> 232	<b>1,950</b> 232	<b>1,776</b> 232	<b>1,455</b> 232
Reserves	820	2,713	2,967	3,238	3,542	3,842	4,275	4,843
Fotal owners' equity	1,255	3,319	3,574	3,845	4,148	4,448	4,881	5,449
Fotal equity & liabilities	4,233	5,321	5,728	6,868	7,605	7,963	8,284	8,461
Cashflow statement								
Operating activities	304	436	511	609	717	673	880	1,125
nvesting activities	970	(703)	(930)	(1,249)	(768)	(304)	(200)	(235)
Financing activities	(1,377)	587 319	41 (378)	614	149 98	(415)	(631)	(844)
Change in cash CAPEX	(102) (372)	(518)	(378) (918)	(26) (1,233)	98 (747)	(45) (273)	50 (157)	45 (181)
Ending cash balance	(372) 214	534	(918) <b>156</b>	(1,233) <b>130</b>	(747) 228	(273) <b>183</b>	233	278
iquidity ratios								
Current ratio (x)	1.3	2.0	1.6	1.3	1.2	1.4	1.6	1.8
Quick ratio (x)	1.1	1.4	1.4	1.2	1.1	1.2	1.4	1.6
Profitability ratios								
Gross profit margin	26.5%	25.0%	24.6%	24.7%	25.2%	23.5%	23.7%	24.2%
Dperating margin	14.4%	12.9%	11.9%	12.6%	13.4%	10.8%	11.6%	13.1%
BITDA margin	20.4%	18.4%	19.0%	21.0%	22.4%	18.8%	18.7%	20.0%
let profit margin Return on assets	12.0% 6.0%	10.3% 6.0%	11.3% 6.4%	10.6% 5.8%	10.8% 5.6%	8.8% 5.3%	10.0% 6.9%	11.5% 8.6%
Return on assets	6.0% 16.4%	6.0% 12.6%	6.4% 10.3%	5.8% 9.9%	5.6% 10.1%	5.3% 9.5%	6.9% 12.0%	8.6% 14.0%
everage ratio	10.T/0	12.0/0	10.0 /0	0.070	10.170	0.070	12.0 /0	14.0 %
Debt / equity (x)	1.37	0.16	0.20	0.37	0.41	0.33	0.21	0.07
Aarket/valuation ratios	1.07	0.10	0.20	0.07	0.11	0.00	0.21	0.07
EV/sales (x)	6.4	5.6	3.3	3.2	3.0	2.4	1.9	1.6
EV/EBITDA (x)	31.3	30.6	17.2	15.2	13.4	12.7	10.0	7.9
/larket-Cap	13,340	15,730	9,790	9,790	9,790	9,790	9,790	9,790
P/E ratio (x)	47.7	51.4	27.6	26.6	24.2	23.9	17.4	13.6
P/BV ratio (x)	10.6	4.7	2.7	2.5	2.4	2.2	2.0	1.8
DY (%)	8.7%	0.4%	0.7%	0.7%	0.8%	0.9%	1.2%	1.5%

Sources: AlJazira Capital, Company Financials \*Prices as of 29th May 2025





Head of Sell-Side Research - Director

Jassim Al-Jubran

+966 11 2256248

j.aljabran@aljaziracapital.com.sa

**RESEARCH DIVISION** 

RESEARCH DIVISION

RATING TERMINOLOGY AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

- 1. Overweight: This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
- 2. Underweight: This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
- 3. Neutral: The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
- 4. Suspension of rating or rating on hold (SR/RH): This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

#### Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of securities, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but AI-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. Some securities maybe, by nature, of low volume/trades, or may become so, unexpectedly in special circumstances, and this might increase the risk on the investor. Some fees might be levied on some investments in securities. Aljazira Capital, its employees, one or more of its board members, its affiliates, or its clients may have investments in the securities or assets referred to in this report. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068